Skip to main
  1. Stocks
  2. Ardelyx
  3. Forecast
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx is favored because IBSRELA continues to show strong underlying demand, with 3Q revenue of $96.3M up 23% year over year and management expanding reimbursement support, pharmacy-network utilization, and the sales force to convert more prescriptions into filled scripts without relying on a broad pricing reset. Gross margins above 95% and a 3Q GAAP net loss of just $0.7M suggest meaningful operating leverage, while FY26 OpEx is guided below $500M and the company remains on track for improved profitability as revenue scales. The outlook is further strengthened by ACCEL enrolling ahead of schedule with Phase 3 data expected in 2H27, the potential for CIC to roughly double IBSRELA’s addressable market, and added patent protection extending the tenapanor franchise into 2041.

Bears say

Ardelyx is vulnerable to regulatory uncertainty because it may rely on accelerated approval strategies, yet regulators can still demand additional data or longer studies that delay commercialization and raise development costs. Its ability to gain traction also depends on securing product labels with favorable features, and any weaker-than-expected labeling could materially limit physician adoption and market penetration for IBSRELA and XPHOZAH. In addition, changes in reimbursement pricing structures could pressure realized sales and margins, making the company’s commercial execution more fragile even after approval.

Ardelyx (ARDX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Ardelyx (ARDX) Analyst Forecast & Price Prediction

Get the latest Ardelyx (ARDX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Ardelyx (ARDX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Ardelyx (ARDX) Analyst Forecast & Price Prediction

Get the latest Ardelyx (ARDX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Ardelyx (ARDX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ARDX stock data and trends